News & Views

Is there value in measuring Bone Mineral Density in elderly CKD patients?

In our last post we reviewed how patients with CKD 3-5D have an increased risk of fracture compared with the general population, but that analysis into the relationship between CKD and Bone Mineral Density (BMD) has shown mixed results. In this follow-up article we continue our focus on the value…

Read more
Professor Stuart M. Sprague
Expert article by:
Professor Stuart M. Sprague

Date of publication:
October 15, 2012

News & Views

The value of measuring Bone Mineral Density in CKD non-dialysis & dialysis patients

The current Kidney Disease: Improving Global Outcomes (KDIGO) [1] guidelines state: “In patients with CKD stages 3-5D with evidence of CKD-MBD, we suggest that Bone Mineral Density (BMD) testing not be performed routinely, because BMD does not predict fracture risk as it does in the general population, and BMD does…

Read more
Professor Stuart M. Sprague
Expert article by:
Professor Stuart M. Sprague

Date of publication:
October 2, 2012

News & Views

Possible therapeutic strategies to lower FGF-23

Twelve years after the discovery of the hormone FGF-23 (fibroblast growth factor 23), many therapeutic options for targeting FGF-23 levels are emerging. Myles Wolf’s latest review paper [1] addresses the pertinent question as to whether CKD treatment regimens should now be tailored to address FGF-23 levels in addition to those…

Read more

Date of publication:
September 7, 2012

News & Views

Will FGF-23 become a critical marker in CKD management?

Welcome to our third instalment in our FGF-23 series exploring this potential marker and therapeutic target for chronic kidney disease. The position of FGF-23 as a biomarker of bone metabolism is progressing steadily. Last year, Isakova’s seminal study [1] reported that circulating FGF-23 concentrations were an independent predictor of progression…

Read more

Date of publication:
August 24, 2012

News & Views

Can FGF-23 predict clinical outcomes in CKD?

Numerous reports have linked elevated FGF-23 levels to the main adverse clinical outcomes in CKD: progression to end-stage renal disease (ESRD), cardiovascular disease, and death. Cross-sectional studies have also shown that increased FGF-23 levels in patients with CKD are associated with adverse systemic effects, increased mortality and deterioration of renal…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
August 13, 2012

News & Views

The clinical significance of FGF-23 in CKD

A proliferation of studies linking excess levels of the endocrine hormone fibroblast growth factor 23 (FGF-23) to adverse renal and cardiovascular outcomes in patients with Chronic Kidney Disease (CKD) is setting the stage for new clinical trials, which could lead to FGF-23 becoming an important marker and/or therapeutic target in…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
July 30, 2012

News & Views

CompAct Survey results of the ERA-EDTA 2012

The CompAct Survey started in November 2011 at the ASN congress in Philadelphia. Now the survey was conducted at the ERA-EDTA congress in Paris in May 2012. At this occasion 86 healthcare professionals participated and the overall results so far have been analyzed: In general, the survey results correspond to…

Read more

Date of publication:
July 23, 2012

News & Views

Our thoughts on the ERA-EDTA Congress 2012

Over 8.500 delegates descended on Paris in the early summer sun for the ERA-EDTA Congress 2012. A few key topics in CKD-MBD received valuable discussion during the sessions on Friday and Saturday. Here are some of our highlights: In Friday’s late breaking clinical trial session, former ERA-EDTA president Prof. Jorge B….

Read more

Date of publication:
June 28, 2012

News & Views

Does phosphate binder treatment confer a survival benefit on treated patients? (Part II)

Until recently, evidence has been lacking that directly associates phosphate binder treatment with reduced mortality. In Part 1 of our article, we examined several recent studies that have investigated this association. Two studies [1] [2] in particular have shown mortality reductions of 25% associated with phosphate binder use. However, these and…

Read more

Date of publication:
June 1, 2012

News & Views

What are the causes of patient non-adherence to hyperphosphatemia treatment? (Part II)

Previously in our series on non-adherence, we assessed how improved patient education could positively impact the 50%+ non-compliance rate in hyperphosphatemia treatment. In this article we assess the following questions: How does a patient’s drug preference impact their adherence to treatment? Why do patients prefer some treatments over others? How does…

Read more

Date of publication:
May 29, 2012

Login

You are about to leave Compact-Renal.com

Clicking the "Continue" link below will take you to an external website. Compact Renal is not responsible for the contents of any external website. Compact Renal is providing these links to you as a convenience, and the inclusion of any links does not imply endorsement of the linked site by Compact Renal.

Do you wish to continue?

Continue Cancel